339 related articles for article (PubMed ID: 25797568)
1. Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study.
Trip AK; Stiekema J; Visser O; Dikken JL; Cats A; Boot H; van Sandick JW; Jansen EP; Verheij M
Acta Oncol; 2015 Nov; 54(10):1754-62. PubMed ID: 25797568
[TBL] [Abstract][Full Text] [Related]
2. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
[TBL] [Abstract][Full Text] [Related]
3. Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010.
Fontana E; Smyth EC; Cunningham D; Rao S; Watkins D; Allum WH; Thompson J; Waddell T; Peckitt C; Chau I; Starling N
Gastric Cancer; 2016 Oct; 19(4):1114-1124. PubMed ID: 26541768
[TBL] [Abstract][Full Text] [Related]
4. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.
Lutz MP; Zalcberg JR; Ducreux M; Ajani JA; Allum W; Aust D; Bang YJ; Cascinu S; Hölscher A; Jankowski J; Jansen EP; Kisslich R; Lordick F; Mariette C; Moehler M; Oyama T; Roth A; Rueschoff J; Ruhstaller T; Seruca R; Stahl M; Sterzing F; van Cutsem E; van der Gaast A; van Lanschot J; Ychou M; Otto F;
Eur J Cancer; 2012 Nov; 48(16):2941-53. PubMed ID: 22921186
[TBL] [Abstract][Full Text] [Related]
5. Variations among 5 European countries for curative treatment of resectable oesophageal and gastric cancer: A survey from the EURECCA Upper GI Group (EUropean REgistration of Cancer CAre).
Messager M; de Steur WO; van Sandick JW; Reynolds J; Pera M; Mariette C; Hardwick RH; Bastiaannet E; Boelens PG; van deVelde CJ; Allum WH;
Eur J Surg Oncol; 2016 Jan; 42(1):116-22. PubMed ID: 26461256
[TBL] [Abstract][Full Text] [Related]
6. Controversies in the treatment of local and locally advanced gastric and esophageal cancers.
Cohen DJ; Leichman L
J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302
[TBL] [Abstract][Full Text] [Related]
7. Current trends in multimodality treatment of esophageal and gastroesophageal junction cancer - Review article.
Klevebro F; Ekman S; Nilsson M
Surg Oncol; 2017 Sep; 26(3):290-295. PubMed ID: 28807249
[TBL] [Abstract][Full Text] [Related]
8. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer.
Bystricky B; Okines AF; Cunningham D
Drugs; 2011 Mar; 71(5):541-55. PubMed ID: 21443280
[TBL] [Abstract][Full Text] [Related]
9. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.
Klevebro F; Lindblad M; Johansson J; Lundell L; Nilsson M
Br J Surg; 2016 Dec; 103(13):1864-1873. PubMed ID: 27689845
[TBL] [Abstract][Full Text] [Related]
10. Oesophagogastric junction adenocarcinoma: which therapeutic approach?
Mariette C; Piessen G; Briez N; Gronnier C; Triboulet JP
Lancet Oncol; 2011 Mar; 12(3):296-305. PubMed ID: 21109491
[TBL] [Abstract][Full Text] [Related]
11. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
[TBL] [Abstract][Full Text] [Related]
12. Site distribution of oesophagogastric cancer.
Byrne JP; Mathers JM; Parry JM; Attwood SE; Bancewicz J; Woodman CB
J Clin Pathol; 2002 Mar; 55(3):191-4. PubMed ID: 11896070
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
14. [Resectable adenocarcinoma of the oesophagogastric junction care: which perioperative treatment?].
Créhange G; Bonnetain F; Chauffert B; Rat P; Bedenne L; Maingon P
Cancer Radiother; 2008 Sep; 12(5):365-73. PubMed ID: 18420440
[TBL] [Abstract][Full Text] [Related]
15. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
[TBL] [Abstract][Full Text] [Related]
16. The current role of staging laparoscopy in oesophagogastric cancer.
Convie L; Thompson RJ; Kennedy R; Clements WD; Carey PD; Kennedy JA
Ann R Coll Surg Engl; 2015 Mar; 97(2):146-50. PubMed ID: 25723693
[TBL] [Abstract][Full Text] [Related]
17. Defining a positive circumferential resection margin in oesophageal cancer and its implications for adjuvant treatment.
O'Neill JR; Stephens NA; Save V; Kamel HM; Phillips HA; Driscoll PJ; Paterson-Brown S
Br J Surg; 2013 Jul; 100(8):1055-63. PubMed ID: 23616367
[TBL] [Abstract][Full Text] [Related]
18. Distant Oncologic Outcome of Patients with Locally Advanced Unresectable and Metastatic Esophageal Cancer after Multimodality Treatment.
Anghel R; Constantinoiu S; Bacinschi X; Gales L; Toma RV; Trifanescu O
Chirurgia (Bucur); 2018; 113(1):116-122. PubMed ID: 29509538
[No Abstract] [Full Text] [Related]
19. Multidisciplinary cancer care may impact on the postoperative mortality and survival of patients with oesophageal and oesophagogastric junction cancer: a retrospective cohort study.
Galán M; Farran L; Aliste L; Hormigo G; Aranda H; Bettonica C; Boladeras AM; Botargues JM; Calvo M; Creus G; De Lama ME; Gornals JB; Mast R; Miró M; Paúles MJ; Robles J; Virgili N; Borràs JM
Clin Transl Oncol; 2015 Mar; 17(3):247-56. PubMed ID: 25520158
[TBL] [Abstract][Full Text] [Related]
20. [Current status and future perspectives of multimodality treatment for esophageal cancer in Japan].
Ando N
Nihon Shokakibyo Gakkai Zasshi; 2014 Feb; 111(2):243-52. PubMed ID: 24500313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
